A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Clinical Trial Grant
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Biogen, Inc.
Start Date
January 10, 2018
End Date
August 16, 2021
Administered By
Neurology, MS & Neuroimmunology
Awarded By
Biogen, Inc.
Start Date
January 10, 2018
End Date
August 16, 2021